Notice of Meeting: Secretary's Advisory Committee on Genetics, Health, and Society, 33235 [07-2964]
Download as PDF
<![CDATA[
jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 72, No. 115 / Friday, June 15, 2007 / Notices
section 2119 of the Act, 42 U.S.C.
300aa–19, as added by Public Law 99–
660 and amended, HRSA is requesting
nominations for three voting members
of the ACCV.
The ACCV advises the Secretary on
the implementation of the VICP. The
activities of the ACCV include:
recommending changes in the Vaccine
Injury Table at its own initiative or as
the result of the filing of a petition;
advising the Secretary in implementing
section 2127 regarding the need for
childhood vaccination products that
result in fewer or no significant adverse
reactions; surveying Federal, State, and
local programs and activities related to
gathering information on injuries
associated with the administration of
childhood vaccines, including the
adverse reaction reporting requirements
of section 2125(b); advising the
Secretary on the methods of obtaining,
compiling, publishing, and using
credible data related to the frequency
and severity of adverse reactions
associated with childhood vaccines; and
recommending to the Director of the
National Vaccine Program that vaccine
safety research be conducted on various
vaccine injuries.
The ACCV consists of nine voting
members appointed by the Secretary as
follows: (1) Three health professionals,
who are not employees of the United
States Government and have expertise
in the health care of children, and the
epidemiology, etiology, and prevention
of childhood diseases, and the adverse
reactions associated with vaccines, at
least two shall be pediatricians; (2) three
members from the general public, at
least two shall be legal representatives
(parents or guardians) of children who
have suffered a vaccine-related injury or
death; and (3) three attorneys, at least
one shall be an attorney whose specialty
includes representation of persons who
have suffered a vaccine-related injury or
death, and one shall be an attorney
whose specialty includes representation
of vaccine manufacturers. In addition,
the Director of the National Institutes of
Health, the Assistant Secretary for
Health, the Director of the Centers for
Disease Control and Prevention, and the
Commissioner of the Food and Drug
Administration (or the designees of such
officials) serve as nonvoting ex officio
members.
Specifically, HRSA is requesting
nominations for three voting members
of the ACCV representing: (1) A
pediatrician who has expertise in the
health care of children, the
epidemiology, etiology, and prevention
of childhood diseases, and the adverse
reactions associated with vaccines; (2) a
member of the general public who is the
VerDate Aug<31>2005
19:26 Jun 14, 2007
Jkt 211001
legal representative of a child who has
suffered a vaccine injury or death; and
(3) an attorney whose specialty includes
representation of persons who have
suffered vaccine injuries or deaths.
Nominees will be invited to serve a 3year term beginning January 1, 2008,
and ending December 31, 2010.
Interested persons may nominate one
or more qualified persons for
membership on the ACCV. Nominations
shall state that the nominee is willing to
serve as a member of the ACCV and
appears to have no conflict of interest
that would preclude the ACCV
membership. Potential candidates will
be asked to provide detailed information
concerning consultancies, research
grants, or contracts to permit evaluation
of possible sources of conflicts of
interest. A curriculum vitae or resume
should be submitted with the
nomination.
The Department of Health and Human
Services has special interest in assuring
that women, minority groups, and the
physically disabled are adequately
represented on advisory committees;
and therefore, extends particular
encouragement to nominations for
appropriately qualified female,
minority, or disabled candidates.
Dated: June 11, 2007.
Caroline Lewis,
Associate Administrator for Management.
[FR Doc. E7–11548 Filed 6–14–07; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Meeting: Secretary’s
Advisory Committee on Genetics,
Health, and Society
Pursuant to Public Law 92–463,
notice is hereby given of the thirteenth
meeting of the Secretary’s Advisory
Committee on Genetics, Health, and
Society (SACGHS), U.S. Public Health
Service. The meeting will be held from
on Tuesday, July 10, 2007, from 8:30
a.m. to approximately 5 p.m. in Room
800 of the Hubert H. Humphrey
Building, 200 Independence Avenue,
SW., Washington, DC 20001. The
meeting will be open to the public with
attendance limited to space available.
The meeting also will be Web cast.
The meeting will focus primarily on
the issue of gene patents and licensing
practices and consist of a series of
presentations and discussions involving
international experts on how other
countries are addressing questions
related to the impact of gene patents and
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
33235
licensing practices on patient access to
genetic tests. In addition, the SACGHS
task force on oversight of genetic testing
will present a brief report on the
progress of its fact-finding and
consultative efforts with regard to the
Secretary’s charge. The Committee will
also be updated about the public
comments received in response to the
Committee’s solicitation on its draft
report on pharmacogenomics.
Time will be provided for public
comments. The Committee would
welcome hearing from anyone wishing
to provide public comment on any issue
related to genetics, health, and society.
Individuals who would like to provide
public comment should notify the
SACGHS Executive Secretary, Ms. Sarah
Carr, by telephone at 301–496–9838 or
e-mail at carrs@od.nih.gov. The
SACGHS office is located at 6705
Rockledge Drive, Suite 750, Bethesda,
MD 20892. Anyone planning to attend
the meeting who is in need of special
assistance, such as sign language
interpretation or other reasonable
accommodations, is also asked to
contact the Executive Secretary.
Under authority of 42 U.S.C. 217a,
Section 222 of the Public Health Service
Act, as amended, the Department of
Health and Human Services established
SACGHS to serve as a public forum for
deliberations on the broad range of
human health and societal issues raised
by the development and use of genetic
and genomic technologies and, as
warranted, to provide advice on these
issues. The draft meeting agenda and
other information about SACGHS,
including information about access to
the Web cast, will be available at the
following Web site: https://
www4.od.nih.gov/oba/sacghs.htm.
Dated: June 7, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–2964 Filed 6–14–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary &
Alternative Medicine, Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
E:\FR\FM\15JNN1.SGM
15JNN1
]]>Agencies
[Federal Register Volume 72, Number 115 (Friday, June 15, 2007)]
[Notices]
[Page 33235]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-2964]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Meeting: Secretary's Advisory Committee on Genetics,
Health, and Society
Pursuant to Public Law 92-463, notice is hereby given of the
thirteenth meeting of the Secretary's Advisory Committee on Genetics,
Health, and Society (SACGHS), U.S. Public Health Service. The meeting
will be held from on Tuesday, July 10, 2007, from 8:30 a.m. to
approximately 5 p.m. in Room 800 of the Hubert H. Humphrey Building,
200 Independence Avenue, SW., Washington, DC 20001. The meeting will be
open to the public with attendance limited to space available. The
meeting also will be Web cast.
The meeting will focus primarily on the issue of gene patents and
licensing practices and consist of a series of presentations and
discussions involving international experts on how other countries are
addressing questions related to the impact of gene patents and
licensing practices on patient access to genetic tests. In addition,
the SACGHS task force on oversight of genetic testing will present a
brief report on the progress of its fact-finding and consultative
efforts with regard to the Secretary's charge. The Committee will also
be updated about the public comments received in response to the
Committee's solicitation on its draft report on pharmacogenomics.
Time will be provided for public comments. The Committee would
welcome hearing from anyone wishing to provide public comment on any
issue related to genetics, health, and society. Individuals who would
like to provide public comment should notify the SACGHS Executive
Secretary, Ms. Sarah Carr, by telephone at 301-496-9838 or e-mail at
carrs@od.nih.gov. The SACGHS office is located at 6705 Rockledge Drive,
Suite 750, Bethesda, MD 20892. Anyone planning to attend the meeting
who is in need of special assistance, such as sign language
interpretation or other reasonable accommodations, is also asked to
contact the Executive Secretary.
Under authority of 42 U.S.C. 217a, Section 222 of the Public Health
Service Act, as amended, the Department of Health and Human Services
established SACGHS to serve as a public forum for deliberations on the
broad range of human health and societal issues raised by the
development and use of genetic and genomic technologies and, as
warranted, to provide advice on these issues. The draft meeting agenda
and other information about SACGHS, including information about access
to the Web cast, will be available at the following Web site: https://
www4.od.nih.gov/oba/sacghs.htm.
Dated: June 7, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-2964 Filed 6-14-07; 8:45 am]
BILLING CODE 4140-01-M
